National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Ponesimod (Ponvory®). HTA ID: 21036

Ponesimod is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.


NCPE Assessment Process Complete
Rapid review commissioned 30/08/2021
Rapid review completed 08/10/2021
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that ponesimod (Ponvory®) not be considered for reimbursement at the submitted price. *


*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.